<DOC>
	<DOCNO>NCT01982500</DOCNO>
	<brief_summary>Investigators propose ass , safety tolerability profile ( number participant adverse event ) bevacizumab ( Avastin ) add chemotherapy front-line treatment epithelial ovarian cancer , fallopian tube carcinoma primary peritoneal carcinoma</brief_summary>
	<brief_title>Observation Bevacizumab Plus Front-line Chemotherapy Patients With Ovarian Cancer</brief_title>
	<detailed_description>In last decade , clinical study bevacizumab ( Avastin ) various tumor show encouraging result term efficacy/safety . However data generate Greek population regard safety efficacy bevacizumab front line Ovarian Cancer . Two prior global phase III randomize trial show addition concurrent bevacizumab standard chemotherapy maintenance bevacizumab significantly increase PFS patient advance ovarian cancer It would relevant document real life clinical data bevacizumab combination chemotherapy ( paclitaxel/carboplatin ) Front Line Ovarian Cancer prescribe medical oncologist Greece .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Written inform consent Age ≥18 year Histologically confirm advanced stage III ( suboptimally debulked &gt; 1cm residual disease ) stage IV ovarian cancer fallopian tube carcinoma primary peritoneal cancer follow surgical debulking aim maximal surgical cytoreduction One measurable lesion ( ≥1cm diameter spiral CT scan ≥2cm conventional technique ) accord RECIST criterion ECOG performance status ≤2 Adequate haematological , renal hepatic function Urine protein &lt; 2+ ( dipstick ) Life expectancy &gt; 12 week Previous front line treatment ovarina cancer Previous radiotherapy target lesion Patients brain metastasis and/or cancerous meningitis Presence history neoplasm except properly treat basal cell skin cancer situ cervical carcinoma Patients participate interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Anti-angiogenic agent</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Front Line</keyword>
</DOC>